Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead

被引：0
|
作者：
Estefania Grotz
Nancy Tateosian
Nicolas Amiano
Maximiliano Cagel
Ezequiel Bernabeu
Diego A. Chiappetta
Marcela A. Moretton
机构：
[1] Universidad de Buenos Aires,Facultad de Farmacia y Bioquímica, Cátedra de Tecnología Farmacéutica I
[2] Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET),Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Química Biológica de la Facultad de Ciencia
[3] Ciudad Universitaria,undefined
来源：
Pharmaceutical Research | 2018年 / 35卷
关键词：
active targeting; nanotechnology; respirable nanocarriers; tuberculosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resistant Mycobacterium tuberculosis (Mtb) strains has put on the spot the necessity of improved TB regimens. In this framework, this review article presents the main relevant research outcomes of nanotechnology in TB. The novel delivery systems for antituberculosis drugs have been discussed. Moreover, the active-targeted nanomedicines to the Mtb reservoirs enlighten the possibility to eradicate low-replicant mycobacteria and diminish latent TB. Finally, we present an overview of the TB socio-economic impact and the cost-related features of TB regimens associated with the use of nanoformulations.
引用
收藏
相关论文
共 50 条
  • [1] Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
    Grotz, Estefania
    Tateosian, Nancy
    Amiano, Nicolas
    Cagel, Maximiliano
    Bernabeu, Ezequiel
    Chiappetta, Diego A.
    Moretton, Marcela A.
    [J]. PHARMACEUTICAL RESEARCH, 2018, 35 (11)
  • [2] Exploring challenges ahead of nanotechnology for biomedicine
    Rau, Julietta V.
    De Santis, Roberto
    Ciofani, Gianni
    [J]. BIOACTIVE MATERIALS, 2017, 2 (03) : 119 - 120
  • [3] Energy efficient automotive networks: state of the art and challenges ahead
    Schmutzler, Christoph
    Krueger, Andreas
    Schuster, Fred
    Simons, Martin
    [J]. INTERNATIONAL JOURNAL OF COMMUNICATION NETWORKS AND DISTRIBUTED SYSTEMS, 2012, 9 (3-4) : 266 - 285
  • [4] Medical visual information retrieval:: State of the art and challenges ahead
    Mueller, Henning
    Zhou, Xin
    Depeursinge, Adrien
    Pitkanen, Mikko
    Iavindrasana, Jimison
    Geissbuhler, Antoine
    [J]. 2007 IEEE INTERNATIONAL CONFERENCE ON MULTIMEDIA AND EXPO, VOLS 1-5, 2007, : 683 - 686
  • [5] Are we done with business process compliance: state of the art and challenges ahead
    Hashmi, Mustafa
    Governatori, Guido
    Lam, Ho-Pun
    Wynn, Moe Thandar
    [J]. KNOWLEDGE AND INFORMATION SYSTEMS, 2018, 57 (01) : 79 - 133
  • [6] Are we done with business process compliance: state of the art and challenges ahead
    Mustafa Hashmi
    Guido Governatori
    Ho-Pun Lam
    Moe Thandar Wynn
    [J]. Knowledge and Information Systems, 2018, 57 : 79 - 133
  • [7] Over-the-Top Content Delivery: State of the Art and Challenges Ahead
    Timmerer, Christian
    Begen, Ali C.
    [J]. PROCEEDINGS OF THE 2014 ACM CONFERENCE ON MULTIMEDIA (MM'14), 2014, : 1231 - 1232
  • [8] Advances in Agriculture Robotics: A State-of-the-Art Review and Challenges Ahead
    Oliveira, Luiz F. P.
    Moreira, Antonio P.
    Silva, Manuel F.
    [J]. ROBOTICS, 2021, 10 (02)
  • [9] End tuberculosis by 2035: challenges ahead
    Malik, Asrar Ahmad
    Sinha, Sanjeev
    Ehtesham, Nasreen Z.
    Hasnain, Seyed E.
    [J]. FUTURE MICROBIOLOGY, 2023, 18 (08) : 461 - 464
  • [10] Tuberculosis: World perspective and the challenges ahead
    Crofton, J
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 : 3 - 6
12345